{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-029768","form_type":"8-K","ticker":"BCDA","cik":"0000925741","company_name":"BioCardia, Inc.","filed_at":"2025-09-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.722967+00:00","generated_at":"2026-05-17T05:51:13.677773+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioCardia regains Nasdaq compliance after raising $7.35M through equity offerings","bullets":["Raised net proceeds of $0.7M (Apr), $0.5M (Jun), $5.1M (Sep public offer), and $1.0M from ATM sales (Apr–Sep 2025).","Believes stockholders' equity now exceeds the $2.5M minimum for continued listing under Nasdaq Rule 5550(b)(1).","Earlier Nasdaq extension to Sep 29, 2025; compliance will be monitored at next periodic report.","Warrants exercisable earlier of 2030 or PMDA approval of CardiAMP Cell Therapy System."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-029768","json":"https://secwatch.observer/filing/0001437749-25-029768.json","markdown":"https://secwatch.observer/filing/0001437749-25-029768.md","text":"https://secwatch.observer/filing/0001437749-25-029768.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774925029768/0001437749-25-029768-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774925029768/bcda20250923_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:51:13.677773+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7ddeb4626309e8c9b45bb6c0d7ff570f815d238e","claim":"BioCardia, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"April 1, 2025, BioCardia, Inc. (the “Company,” “we,” “us” and “our”) received a notification letter (the “Notice”) from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its amount of stockholders’ equity had fallen below the $2,500,000 required minimum for continued listing set forth in Nasdaq Listing Rule 5550(b)(1). As noted in the Original 8-K, the Company had until May 16, 2025 to provide Nasdaq with a specific plan to achieve and sustain compliance. The Company submitted its plan to regain compliance on May 15, 2025","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/925741/000143774925029768/0001437749-25-029768-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"noncompliance notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}